BioMarin Pharmaceutical has withdrawn its EU marketing authorization application (MAA) for Roctavian (valoctocogene roxaparvovec), the gene therapy it is developing for severe hemophilia A that also recently suffered a setback in the US.
The company has pulled the filing because it cannot provide the data that the European Medicines Agency has asked for during the current regulatory review of the MAA
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?